一、关于公司2023年半年度募集资金存放与使用情况专项报告的独立意见 经核查，我们认为：公司编制的《募集资金2023年半年度存放与使用情况 的专项报告》内容真实、准确、完整，不存在虚假记载、误导性陈述和重大遗 漏。2023年半年度，公司募集资金的管理和使用符合中国证监会、深圳证券交 易所关于上市公司募集资金使用和管理的相关规定，不存在违反募集资金管理 和使用相关规定、损害股东利益的情形。 江苏爱朋医疗科技股份有限公司独立董事 关于第三届董事会第五次会议相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所上市公司自律监管指引 第2号——创业板上市公司规范运作》《江苏爱朋医疗科技股份有限公司章程》 （以下简称"《公司章程》"）《江苏爱朋医疗科技股份有限公司独立董事工 作制度》等相关法律、行政法规、规章制度的有关规定，作为公司的独立董 事，本着严谨、负责的态度，对江苏爱朋医疗科技股份有限公司（以下简称 "公司"）第三届董事会第五次会议审议的相关事项进行监督和审议，基于独 立判断立场，发表如下独立意见： 陶宏迅（签字）： 江苏爱朋医疗科技股份有限公司 2023年8月28日 二、关于控股股东、实际控制人及其 ...

Financial Performance - 2022 annual revenue was 323.8081 million yuan, a decrease of 29.79% year-on-year [7] - Pain management business revenue was 117.3916 million yuan, down 53.46% year-on-year [7] - Nasal care business revenue was 126.1041 million yuan, down 5.82% year-on-year [7] - Net profit attributable to shareholders was -76.3774 million yuan, a decrease of 241.27% year-on-year [7] - Q1 2023 revenue was 94.0682 million yuan, up 29.22% year-on-year [11] - Q1 2023 net profit was 1.2156 million yuan, up 111.06% year-on-year [11] Business Segments Pain Management - Focused on acute, chronic, and intractable pain management [11] - New non-DEHP material infusion devices launched for pregnant women and adolescents [11] - Developed MCB pump + non-DEHP infusion device + iPainfree pain management system [7] - Expanding into non-public hospitals and non-anesthesia departments [11] Nasal and Upper Airway Management - Nasal care products revenue accounted for 38.94% of total revenue in 2022 [10] - Retail business revenue reached 107.1526 million yuan, up 14.26% year-on-year [10] - Expanded indications for Noseclean nasal spray to include acute upper respiratory infections [10] - Increased online investment in nasal care products [7] CXO Business - Established medical device CXO project incubation centers in 2020 [8] - Provides capital, R&D, registration, production, and marketing support [8] - Set up a 50 million yuan private equity fund for project incubation [8] R&D and Innovation - 2022 R&D investment was 34.9463 million yuan, accounting for 10.79% of revenue [9] - 16 R&D projects across 9 major categories in pain and nasal management [9] - Key projects include pain assessment algorithms, anesthesia depth monitors, and nasal irrigation materials [9] - Launched new products including Noseclean nasal spray and non-DEHP infusion devices [9] Market Trends and Opportunities - Domestic anesthesia depth monitors gaining market share due to government procurement policies [8] - Epidural analgesia included in medical insurance in over 10 provinces [11] - Nasal irrigation market potential supported by COVID-19 expert consensus [12] - Allergic rhinitis prevalence in China is 17.6% [12] Strategic Initiatives - Building a smart product and service ecosystem focused on single disease management [5] - Expanding into perioperative rapid recovery and medical aesthetic safety [7] - Strengthening market access and hospital entry for new products [7] - Enhancing brand exposure and customer loyalty for nasal care products [7]

证券代码：300753 证券简称：爱朋医疗 公告编号：2023-020 江苏爱朋医疗科技股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）已于2023年4月24日在 巨潮资讯网（http://www.cninfo.com.cn）上披露了《2022年年度报告》全文及其摘 要。 特此公告。 江苏爱朋医疗科技股份有限公司董事会 2023 年5月8日 为了便于投资者更全面地了解公司2022年度经营情况，公司定于2023年5月16 日（星期二）15:00-17:00 举行2022年度网上业绩说明会，本次年度业绩说明会将通 过深圳证券交易所提供的"互动易"平台举行，投资者可登陆"互动易" 网站 （http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次业绩说明会。 出席本次业绩说明会的人员有：公司董事长王凝宇先生、副总经理兼财务总监 袁栋麒先生、副总经理兼董事会秘书缪飞先生、独立董事侯利阳先生。 为充分尊重投资者，提升公司与投资者的交流效率和针对性， ...

江苏爱朋医疗科技股份有限公司2022年年度报告全文 江苏爱朋医疗科技股份有限公司 2022 年年度报告 ...

Financial Performance - The company's revenue for Q1 2023 was ¥94,068,177.53, representing a 29.22% increase compared to ¥72,794,357.61 in the same period last year[5] - Net profit attributable to shareholders was ¥1,215,574.66, a significant turnaround from a loss of ¥10,987,817.03 in the previous year, marking an increase of 111.06%[5] - The net profit after deducting non-recurring gains and losses was ¥975,082.81, compared to a loss of ¥10,948,474.02 last year, reflecting an increase of 108.91%[5] - Operating profit for Q1 2023 was CNY 2,768,976.71, a significant recovery from a loss of CNY 12,312,975.32 in the same period last year[19] - Net profit for Q1 2023 was CNY 1,250,235.16, compared to a net loss of CNY 11,460,471.11 in Q1 2022, marking a turnaround in profitability[19] - The company reported a basic and diluted earnings per share of CNY 0.0096, recovering from a loss of CNY 0.0872 per share in the previous year[19] Cash Flow - Cash flow from operating activities showed a net outflow of ¥60,865,461.63, slightly worsening from a net outflow of ¥58,957,573.53 in the same period last year, a change of -3.24%[5] - Cash generated from operating activities was CNY 80,064,517.56, up from CNY 74,541,426.93 in Q1 2022, indicating improved cash flow[21] - The net cash flow from operating activities for Q1 2023 was -60,865,461.63 CNY, compared to -58,957,573.53 CNY in Q1 2022, indicating a slight increase in cash outflow[22] - Total cash inflow from operating activities was 87,834,681.51 CNY, while cash outflow totaled 148,700,143.14 CNY, resulting in a net cash flow deficit[22] - Cash flow from investing activities showed a net outflow of -142,921,162.72 CNY, significantly higher than -62,097,328.20 CNY in the same period last year[22] - Cash flow from financing activities resulted in a net outflow of -1,463,619.19 CNY, contrasting with a net inflow of 9,563,006.67 CNY in Q1 2022[22] - The ending balance of cash and cash equivalents was 43,501,364.85 CNY, down from 162,770,955.50 CNY at the end of Q1 2022[22] Assets and Liabilities - The company's total assets decreased by 5.07% to ¥826,125,197.49 from ¥870,213,234.55 at the end of the previous year[5] - Total liabilities decreased to CNY 138,512,800.30 from CNY 183,851,072.51, indicating a reduction in financial obligations[17] - The company’s equity attributable to shareholders increased to CNY 686,795,935.87 from CNY 685,580,361.21, showing slight growth in shareholder value[17] - The total current assets decreased from CNY 445,382,651.89 at the beginning of the year to CNY 400,705,725.07 by the end of the quarter, representing a decline of approximately 10%[15] - The total non-current assets slightly decreased from CNY 261,860,629.26 to CNY 261,498,926.17, a marginal decline of around 0.14%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,800[9] - The company reported a reduction in restricted shares from 51,567,575 to 45,053,063, a decrease of approximately 13%[11] - Shareholder Zhang Zhihui reduced his holdings by 252,000 shares, accounting for 1.9992% of the total share capital[13] - Shareholder Guan Jifeng reported a reduction of 190,962 shares, representing 0.16% of the total share capital[13] Investments and R&D - The company’s investment activities resulted in a cash outflow of ¥142,921,162.72, which is a 130.16% increase compared to ¥62,097,328.20 in the same period last year[8] - The company has ongoing investments in long-term equity, with a slight decrease from CNY 50,125,753.65 to CNY 49,917,203.04[15] - Research and development expenses for Q1 2023 were CNY 9,687,121.04, slightly down from CNY 10,224,739.54 in Q1 2022, indicating a focus on cost management[18] Other Information - The company reported a significant increase in accounts receivable notes by 655.51%, reaching ¥11,895,464.09, primarily due to settlements from certain customers[8] - Cash and cash equivalents decreased significantly from CNY 249,251,608.39 to CNY 43,501,364.85, a drop of about 83%[15] - Accounts receivable increased from CNY 110,834,769.72 to CNY 122,070,035.20, indicating a growth of approximately 10%[15] - Inventory rose from CNY 61,039,583.17 to CNY 68,062,416.37, reflecting an increase of about 11%[15] - The company is focusing on expanding its market presence and developing new technologies, although specific figures were not disclosed in the report[13] - The first quarter report was not audited[23]

证券代码：300753 证券简称：爱朋医疗 江苏爱朋医疗科技股份有限公司 投资者关系活动记录表 编号：2022-007 | --- | --- | --- | |-------------------------|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2020-001 证券代码：300753 证券简称：爱朋医疗 江苏爱朋医疗科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | ☑ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 登录"全景• 路演天下"（ | http://rs.p5w.net ）的投资者。 | | 人员姓名 | | | | 时间 | 2020 年 4 月 29 日下午 | 15:00-17:00 | | 地点 | 网络远程方式 | | | 上市公司接待人 | | 董事长王凝宇先生、副总经理兼财务总监袁栋麒先生、副总经 | | 员姓名 | | 理兼董事会秘书缪飞 ...

编号：2018-004 证券代码：300753 证券简称：爱朋医疗 江苏爱朋医疗科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | R 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 建信基金 师成平；天风证券 郑薇；天风证券 李杨。 | | 人员姓名 | | | | 时间 | 2018 年 12 月 19 日 | | | 地点 | 江苏爱朋医疗科技股份有限公司会议室 | | | 上市公司接待人 | | 董事长王凝宇；董事会秘书缪飞；证券事务代表叶俞飞。 | | 员姓名 | | | | 投资者关系活动 | 1 、公司宣传片播放； | ...